Evidence map›Paper›PMID 25562034›Full record

ArticleBMJ open respiratory research2014

Necessity of amoxicillin clavulanic acid in addition to prednisolone in mild-to-moderate COPD exacerbations.

Marjolein Brusse-Keizer, Paul VanderValk, Ron Hendrix, Huib Kerstjens, Job van der Palen

Open access · goldAbstract read
In one paragraph

Article in BMJ open respiratory research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 3 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 3 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Antibiotics for exacerbations of chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2018
    Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Marjolein Brusse-KeizerDepartment of Pulmonary Medicine , Medisch Spectrum Twente , Enschede , The Netherlands.
Paul VanderValkDepartment of Pulmonary Medicine , Medisch Spectrum Twente , Enschede , The Netherlands.
Ron HendrixRegional Laboratory of Public Health , Enschede , The Netherlands ; Department of Medical Microbiology , University Medical Centre Groningen, and University of Groningen , Groningen , The Netherlands.
Huib KerstjensDepartment of Pulmonary Medicine, and Gro ningen Research Institute for Asthma and COPD (GRIAC) , University Of Groningen, University Medical Centre Groningen , Groningen , The Netherlands.
Job van der PalenDepartment of Pulmonary Medicine , Medisch Spectrum Twente , Enschede , The Netherlands ; Department of Research Methodology, Measurement, and Data Analysis , University of Twente , Enschede , The Netherlands.
Medisch Spectrum Twente · NLUniversity Medical Center Groningen · NLUniversity of Twente · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe effectiveness of antibiotics in chronic obstructive pulmonary disease (COPD) exacerbations is still a matter of debate, especially in outpatients with an intermediate probability of bacterial infection.

methodsIn this study, 35 COPD outpatients diagnosed by their chest physician with moderately severe COPD exacerbation, but without pneumonia, were randomised in a double blind, placebo-controlled study. Patients had one or two of the following characteristics: a positive Gram's stain of the sputum, 2 or more exacerbations in the previous year, a decrease in lung function of >200 mL and >12%. Patients received amoxicillin clavulanic acid (500/125 mg three times daily) or placebo for 7 days, always combined with a course of prednisolone (30 mg/day) for 7 days. Primary outcome was duration of the exacerbation. Additionally, we measured severity of the exacerbation, health-related quality of life, sputum parameters, number of relapses within 28 days and the number of re-exacerbations within 4 months after the study.

resultsThere was no difference observed in time to resolution of the exacerbation between the two groups (HR=1.12; (95% CI 0.5 to 2.3; p=0.77)), nor in any other treatment parameter.

conclusionsWe detected no evidence for the effectiveness of addition of antibiotics to prednisolone for COPD exacerbations of moderate severity and with intermediate probability of bacterial infection in this underpowered study. More placebo-controlled studies are needed to properly define subgroups of COPD outpatients in which antibiotics are of additional value. TRIALS REGISTRATION NUMBER: clinical trial registered with http://www.trialregister.nl/(NTR351).

Indexed as

Bacterial InfectionCOPD ExacerbationsCOPD Pharmacology

Identifiers

PMID25562034
PMCPMC4281527
OpenAlexW2171374042

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.